Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
NCT03642132
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histologically confirmed Stage III IV epithelial ovarian, fallopian tube, or primary peritoneal cancer including carcinosarcoma with high-grade serous component.
- Patients must be candidates for bevacizumab in combination with platinum based chemotherapy and previously untreated.
- Must have completed a primary surgical debulking procedure, or be candidates for neoadjuvant chemotherapy with planned interval debulking surgery.
1. Patients who completed primary debulking must have had incompletely resected disease that is macroscopically/grossly visible and at least with lesions >1 mm and be randomized at a maximum of 8 weeks after surgery.
2. For patients who are candidates for neoadjuvant chemotherapy, the diagnoses must have been confirmed by:
- Core tissue (not fine-needle aspiration) biopsy is required for diagnosis.
- Stage IIIC-IV documented via imaging or surgery (without attempt at cytoreduction).
- Serum CA-125/CEA ratio >25. If the serum CA-125/CEA ratio is <25, then workup should be negative for the presence of a primary gastrointestinal or breast malignancy (<6 weeks before start of neoadjuvant treatment).
- Randomization must occur within 8 weeks after diagnosis.
- Availability of an archival FFPE tumor tissue block or a minimum of 25 slides, together with an accompanying original H&E slide. If archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies. Tumor tissue must contain 40% or greater tumor nuclei per central laboratory assessment.
- ECOG performance status 0-1
- Age >=18 years (or >=20 years in Japan).
- Adequate bone marrow, hepatic, and renal function and blood coagulation
- Non-epithelial tumors or ovarian tumors with low malignant potential (ie, borderline
tumors) or mucinous tumors.
- Patients for whom intraperitoneal cytotoxic chemotherapy is planned.
- Prior exposure to immunotherapy with interleukin (IL)-2, interferon alpha (IFN-α), or
an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte
associated antigen 4 (anti-CTLA4) antibody (including ipilimumab), or any other
antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint
pathways, excluding therapeutic anticancer vaccines.
- Prior treatment with a PARP inhibitor.
- Prior treatment with any anti-vascular endothelial growth factor (VEGF) drug,
including bevacizumab.
- Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any
reason within 4 weeks prior to randomization and/or incomplete recovery from surgery.
- Prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation
for localized cancer of the breast, head and neck, or skin is permitted, provided that
it was completed more than three years prior to registration, and the patient remains
free of recurrent or metastatic disease.
- Prior targeted therapy (including but not limited to vaccines, antibodies, tyrosine
kinase inhibitors) or hormonal therapy for management of their ovarian, peritoneal
primary or fallopian tube carcinoma.
- Prior organ transplantation including allogenic stem cell transplantation.
- Diagnosis of Myelodysplastic Syndrome (MDS).
- Known symptomatic brain metastases requiring steroids. Patients with previously
diagnosed brain metastases are eligible if they have completed their treatment and
have recovered from the acute effects of radiation therapy or surgery prior to study
enrollment, have discontinued corticosteroid treatment for these metastases for at
least 4 weeks and are neurologically stable.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Edmonton, Alberta
- Surrey, British Columbia
- Vancouver, British Columbia
- Halifax, Nova Scotia
- Hamilton, Ontario
- London, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Belo Horizonte, Minas Gerais
- Porto Alegre, Rio Grande Do Sul
- Rio De Janeiro,
- São Paulo,
- São Paulo,
- São Paulo,
- São Paulo,
- The Woodlands, Texas
- Costa Masnaga, Lecco
- Tainan City,
- Roanoke, Virginia
- Copenhagen,
- Kagoshima,
- Cleveland, Ohio
- Seoul,
- Orange, California
- Poznan,
- Bedford, Texas
- Graz,
- Kawasaki, Kanagawa
- Piacenza,
- Shelbyville, Tennessee
- Leuven,
- Taoyuan City,
- Pierre Benite cedex,
- Santa Barbara, California
- Philadelphia, Pennsylvania
- Seoul,
- Caen Cedex 5,
- Dublin,
- Velikiy Novgorod,
- Kernersville, North Carolina
- Cremona,
- Nottingham,
- Calgary, Alberta
- Matsuyama, Ehime
- Louisville, Kentucky
- Praha 2,
- Nice cedex 2,
- Fairway, Kansas
- Asheville, North Carolina
- Krakow,
- London,
- Oslo,
- Boston, Massachusetts
- Prato,
- Singapore,
- Wellington, Florida
- Innsbruck,
- Rogers, Arkansas
- Seoul,
- Nottingham,
- Rybnik,
- Brisbane, Queensland
- Bergen,
- Brussels,
- Tucson, Arizona
- Bergamo,
- Mayfield Heights, Ohio
- Bebington, Wirral, Merseyside
- Dublin 7, Dublin
- Scottsdale, Arizona
- Sutton, Surrey
- Moscow,
- Praha 2,
- Austin, Texas
- Atlanta, Georgia
- Seoul,
- Saint Petersburg,
- Kansas City, Missouri
- Boulder, Colorado
- Cremona,
- Winston-Salem, North Carolina
- Rimini,
- Lugo, Ravenna
- Montreal, Quebec
- Olomouc,
- Phoenix, Arizona
- Milwaukee, Wisconsin
- Chermside, Queensland
- Glasgow,
- Tucson, Arizona
- London,
- Zurich,
- Waterford,
- Fort Worth, Texas
- London,
- Irving, Texas
- Bellinzona, Ticino
- London,
- Chuo-ku, Tokyo
- Goyangsi, Gyeonggi-do
- Cordoba,
- Murfreesboro, Tennessee
- Toon, Ehime
- Madrid,
- Lyon cedex 08,
- Cleveland, Ohio
- Parkville, Victoria
- New Lambton Heights, New South Wales
- Miano, Milano
- Basel, Basel-stadt
- Isehara, Kanagawa
- Winnipeg, Manitoba
- Seoul,
- Auchenflower, Queensland
- Seoul,
- Atlanta, Georgia
- Milwaukee, Wisconsin
- Gallatin, Tennessee
- Mayfield Heights, Ohio
- Candiolo, Torino
- Philadelphia, Pennsylvania
- Daytona Beach, Florida
- Cleveland, Ohio
- Praha 2, Czech Republic
- Dublin,
- Parkville, Victoria
- Taipei City,
- Bethesda, Maryland
- Northwood, Middlesex
- Herston, Queensland
- Bunkyo-ku, Tokyo
- Taipei,
- Manerbio, Brescia
- Zurich,
- Yokohama, Kanagawa
- Boston, Massachusetts
- Girona,
- Vandoeuvre-lès-Nancy,
- London,
- Dublin 4,
- Taoyuan City,
- L'Hospitalet de Llobregat, Barcelona
- Seoul,
- Aurora, Colorado
- Asheville, North Carolina
- Prato,
- Boston, Massachusetts
- Kelowna, British Columbia
- Parkville, Victoria
- Louisville, Kentucky
- Madrid,
- Douglasville, Georgia
- Glasgow, CITY OF Glasgow
- Cartersville, Georgia
- Krakow,
- Singapore,
- Daegu,
- Taipei City,
- Westwood, Kansas
- Toronto, Ontario
- Chelyabinsk,
- Austell, Georgia
- Stockport,
- Edmonton, Alberta
- Halifax, Nova Scotia
- Headington, Oxford
- West Palm Beach, Florida
- Winnipeg, Manitoba
- South Brisbane, Queensland
- Halifax, Nova Scotia
- Silver Spring, Maryland
- Hermitage, Tennessee
- Toronto, Ontario
- Tsukuba, Ibaraki
- Hamamatsu, Shizuoka
- Taipei,
- Oslo,
- Luzern 16, Luzern
- Newcastle, New South Wales
- Dickson, Tennessee
- Gent, EAST Flanders
- Herston, Queensland
- Melbourne, Victoria
- Albuquerque, New Mexico
- Namur,
- Nashville, Tennessee
- Taipei city,
- London,
- Dublin 4,
- Piacenza,
- Praha 5,
- Zurich,
- Fayetteville, Arkansas
- Bebington, Wirral, Merseyside
- Silver Spring, Maryland
- Winnipeg, Manitoba
- Pyatigorsk, Stavropol Region
- Taipei City,
- Taipei,
- Hidaka, Saitama
- Brescia,
- Debrecen,
- Paris cedex 15,
- Nashville, Tennessee
- Nizhniy Novgorod,
- Nashville, Tennessee
- Niigata,
- Louisville, Kentucky
- Louisville, Kentucky
- Nashville, Tennessee
- Kortrijk,
- Phoenix, Arizona
- Kita-adachi-gun, Saitama
- Philadelphia, Pennsylvania
- Ottawa, Ontario
- Singapore,
- Maastricht,
- Chelyabinsk,
- Praha 2,
- Aalborg,
- Roanoke, Virginia
- Austin, Texas
- Montreal, Quebec
- Marietta, Georgia
- Torino,
- Milano,
- Dublin,
- Franklin, Tennessee
- Sutton, Surrey
- Poznan,
- Dublin 7, Dublin
- Sapporo, Hokkaido
- Irving, Texas
- Southport, Queensland
- Hong Kong,
- Ostrava-Poruba,
- Malvern, Victoria
- Cleveland, Ohio
- Budapest,
- Manchester,
- Lakewood, Colorado
- Singapore,
- Groningen,
- Lebanon, Tennessee
- Smyrna, Tennessee
- Paris,
- Rybnik,
- Seoul,
- Reno, Nevada
- Nashville, Tennessee
- Zurich,
- South Brisbane, Queensland
- Athens/New Kifissia,
- Debrecen,
- Chandler, Arizona
- Krasnodar,
- Tainan city,
- Atlanta, Georgia
- Auchenflower, Queensland
- Kagoshima,
- Liege,
- Cleveland, Ohio
- Groningen,
- Herston, Queensland
- Jerusalem,
- Tempe, Arizona
- Sochi, Krasnodar Region
- Seoul,
- San Antonio, Texas
- Usti nad Labem,
- Olsztyn,
- Louisville, Kentucky
- Brighton, Victoria
- Orenburg,
- Seoul,
- Sendai, Miyagi
- Salt Lake City, Utah
- Cambridge, Cambridgeshire
- Tokorozawa, Saitama
- Cremona,
- Seoul,
- Bergen,
- Solvang, California
- Montreal, Quebec
- Szolnok,
- Bergamo,
- Albuquerque, New Mexico
- Northampton, Northamptonshire
- Bergamo,
- South Brisbane, Queensland
- Boston, Massachusetts
- Taipei City,
- Olsztyn,
- Madrid,
- Zurich,
- Columbia, Maryland
- Vancouver, British Columbia
- Daegu,
- Shimotsuke, Tochigi
- Basel, Basel-stadt
- Athens,
- Eugene, Oregon
- Hong Kong,
- Villejuif cedex,
- Akashi, Hyogo
- Carrollton, Georgia
- Louisville, Kentucky
- Budapest,
- Leiden,
- Singapore,
- Louisville, Kentucky
- Sevilla,
- Como,
- Chandler, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Tucson, Arizona
- Fayetteville, Arkansas
- Rogers, Arkansas
- Orange, California
- Santa Barbara, California
- Solvang, California
- Aurora, Colorado
- Boulder, Colorado
- Lakewood, Colorado
- Daytona Beach, Florida
- Wellington, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Austell, Georgia
- Carrollton, Georgia
- Cartersville, Georgia
- Douglasville, Georgia
- Marietta, Georgia
- Fairway, Kansas
- Westwood, Kansas
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Bethesda, Maryland
- Columbia, Maryland
- Silver Spring, Maryland
- Silver Spring, Maryland
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Kansas City, Missouri
- Reno, Nevada
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Asheville, North Carolina
- Asheville, North Carolina
- Kernersville, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Cleveland, Ohio
- Mayfield Heights, Ohio
- Mayfield Heights, Ohio
- Eugene, Oregon
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Dickson, Tennessee
- Franklin, Tennessee
- Gallatin, Tennessee
- Hermitage, Tennessee
- Lebanon, Tennessee
- Murfreesboro, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Shelbyville, Tennessee
- Smyrna, Tennessee
- Austin, Texas
- Austin, Texas
- Bedford, Texas
- Fort Worth, Texas
- Irving, Texas
- Irving, Texas
- San Antonio, Texas
- The Woodlands, Texas
- Salt Lake City, Utah
- Roanoke, Virginia
- Roanoke, Virginia
- Milwaukee, Wisconsin
- Milwaukee, Wisconsin
- New Lambton Heights, New South Wales
- Newcastle, New South Wales
- Auchenflower, Queensland
- Auchenflower, Queensland
- Brisbane, Queensland
- Chermside, Queensland
- Herston, Queensland
- Herston, Queensland
- Herston, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- South Brisbane, Queensland
- Southport, Queensland
- Brighton, Victoria
- Malvern, Victoria
- Melbourne, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Parkville, Victoria
- Graz,
- Innsbruck,
- Gent, EAST Flanders
- Brussels,
- Kortrijk,
- Leuven,
- Liege,
- Namur,
- Calgary, Alberta
- Edmonton, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Winnipeg, Manitoba
- Halifax, Nova Scotia
- Halifax, Nova Scotia
- Ottawa, Ontario
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Montreal, Quebec
- Praha 2, Czech Republic
- Olomouc,
- Ostrava-Poruba,
- Praha 2,
- Praha 2,
- Praha 2,
- Praha 5,
- Usti nad Labem,
- Aalborg,
- Copenhagen,
- Caen Cedex 5,
- Lyon cedex 08,
- LYON cedex 8,
- Nice cedex 2,
- Paris cedex 15,
- Paris,
- Pierre Benite cedex,
- Vandoeuvre-lès-Nancy,
- Villejuif cedex,
- Athens/New Kifissia,
- Athens,
- Hong Kong,
- Hong Kong,
- Budapest,
- Budapest,
- Debrecen,
- Debrecen,
- Szolnok,
- Dublin 7, Dublin
- Dublin 7, Dublin
- Dublin 4,
- Dublin 4,
- Dublin,
- Dublin,
- Dublin,
- Waterford,
- Jerusalem,
- Manerbio, Brescia
- Costa Masnaga, Lecco
- Miano, Milano
- Lugo, Ravenna
- Candiolo, Torino
- Bergamo,
- Bergamo,
- Bergamo,
- Brescia,
- Como,
- Cremona,
- Cremona,
- Cremona,
- Milano,
- Piacenza,
- Piacenza,
- Prato,
- Prato,
- Rimini,
- Torino,
- Matsuyama, Ehime
- Toon, Ehime
- Sapporo, Hokkaido
- Akashi, Hyogo
- Tsukuba, Ibaraki
- Isehara, Kanagawa
- Kawasaki, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Hidaka, Saitama
- Kita-adachi-gun, Saitama
- Tokorozawa, Saitama
- Hamamatsu, Shizuoka
- Shimotsuke, Tochigi
- Bunkyo-ku, Tokyo
- Chuo-ku, Tokyo
- Kagoshima,
- Kagoshima,
- Niigata,
- Goyangsi, Gyeonggi-do
- Daegu,
- Daegu,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Seoul,
- Groningen,
- Groningen,
- Leiden,
- Maastricht,
- Bergen,
- Bergen,
- Oslo,
- Oslo,
- Krakow,
- Krakow,
- Olsztyn,
- Olsztyn,
- Poznan,
- Poznan,
- Rybnik,
- Rybnik,
- Sochi, Krasnodar Region
- Pyatigorsk, Stavropol Region
- Chelyabinsk,
- Chelyabinsk,
- Krasnodar,
- Moscow,
- Nizhniy Novgorod,
- Orenburg,
- Saint Petersburg,
- Velikiy Novgorod,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- Singapore,
- L'Hospitalet de Llobregat, Barcelona
- Cordoba,
- Girona,
- Madrid,
- Madrid,
- Madrid,
- Sevilla,
- Basel, Basel-stadt
- Basel, Basel-stadt
- Luzern 16, Luzern
- Bellinzona, Ticino
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Zurich,
- Tainan city,
- Tainan City,
- Taipei city,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei City,
- Taipei,
- Taipei,
- Taipei,
- Taoyuan City,
- Taoyuan City,
- Cambridge, Cambridgeshire
- Glasgow, CITY OF Glasgow
- Bebington, Wirral, Merseyside
- Bebington, Wirral, Merseyside
- Northwood, Middlesex
- Northampton, Northamptonshire
- Headington, Oxford
- Sutton, Surrey
- Sutton, Surrey
- Glasgow,
- London,
- London,
- London,
- London,
- London,
- London,
- Manchester,
- Nottingham,
- Nottingham,
Descriptive Information | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Brief Title ICMJE | Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) | |||||||||
Official Title ICMJE | A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100) | |||||||||
Brief Summary | JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III study, and the decision was based on several factors, including previous announced interim results from JAVELIN Ovarian 100 study (B9991010). Patients who remain in B9991030 study will continue receiving their randomized treatment assigned and will be monitored for appropriate safety assessments until treatment discontinuation. | |||||||||
Detailed Description | JAVELIN Ovarian PARP 100 (B9991030) is an open-label, international, multi-center, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). The primary endpoint is progression-free survival (PFS) as determined based on blinded independent central review (BICR) assessment per RECIST v1.1. On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study. The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial's initiation, including the previously announced interim results from JAVELIN Ovarian 100 study (B9991010), which was stopped due to futility of efficacy at a planned interim analysis on 21 December 2018. The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer. Additional factors include the rapidly changing treatment landscape and the approval of a PARP inhibitor in the frontline maintenance setting. The decision to discontinue the JAVELIN Ovarian PARP 100 trial was not made for safety reasons. Patients who remain in the study will continue receiving investigational products according to their randomized treatment assignment and will be monitored for appropriate safety assessments until treatment discontinuation. | |||||||||
Study Type ICMJE | Interventional | |||||||||
Study Phase ICMJE | Phase 3 | |||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||||||||
Condition ICMJE | Ovarian Cancer | |||||||||
Intervention ICMJE |
| |||||||||
Study Arms ICMJE |
| |||||||||
Publications * | Not Provided | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||||||||
Recruitment Information | ||||||||||
Recruitment Status ICMJE | Active, not recruiting | |||||||||
Actual Enrollment ICMJE | 79 | |||||||||
Original Estimated Enrollment ICMJE | 720 | |||||||||
Estimated Study Completion Date ICMJE | November 28, 2021 | |||||||||
Estimated Primary Completion Date | November 28, 2021 (Final data collection date for primary outcome measure) | |||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||||||||
Sex/Gender ICMJE |
| |||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||||||||
Accepts Healthy Volunteers ICMJE | No | |||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||||||||
Listed Location Countries ICMJE | Australia, Belgium, Ireland, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Taiwan, United States | |||||||||
Removed Location Countries | Croatia, Estonia, Hungary, Poland, Slovakia, Ukraine | |||||||||
Administrative Information | ||||||||||
NCT Number ICMJE | NCT03642132 | |||||||||
Other Study ID Numbers ICMJE | B9991030 2017-004456-30 ( EudraCT Number ) B9991030 ( Other Identifier: Alias Study Number ) JAVELIN OVARIAN PARP 100 ( Other Identifier: Alias Study Number ) | |||||||||
Has Data Monitoring Committee | Yes | |||||||||
U.S. FDA-regulated Product |
| |||||||||
IPD Sharing Statement ICMJE |
| |||||||||
Responsible Party | Pfizer | |||||||||
Study Sponsor ICMJE | Pfizer | |||||||||
Collaborators ICMJE | Not Provided | |||||||||
Investigators ICMJE |
| |||||||||
PRS Account | Pfizer | |||||||||
Verification Date | February 2021 | |||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |